DOCSLIB.ORG

Wake Forest Comprehensive Cancer Center Annual Report 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wake Forest Comprehensive Cancer Center Annual Report 2014 2014 CANCER PROGRAM ANNUAL REPORT WITH 2013 STATISTICS TABLE OF CONTENTS 1 MESSAGE FROM THE DIRECTOR 2 CANCER REGISTRY 4 CANCER COMMITTEE MEMBERS/ CANCER REGISTRY STAFF 5 CANCER ACTIVITIES 23 CANCER DATA 29 PUBLISHED ABSTRACTS Giant Cell Carcinoma Courtesy of Dr. A. Julian Garvin, Department of Pathology 2014 1 CANCER PROGRAM ANNUAL REPORT ANNUAL PROGRAM CANCER Comprehensive Cancer Center AT WAKE FOREST BAPTIST MEDICAL CENTER “ We are extremely proud of the achievements of our Comprehensive Cancer Center as we strive to deliver the best care possible to our patients, their families and caregivers.” – Boris Pasche, MD, PhD, FACP Director, Comprehensive Cancer Center The Comprehensive Cancer Center The Cancer Center recognizes the existing floors, which house all at Wake Forest Baptist Medical the importance of building cross- outpatient oncology services as well Center was founded in the early departmental and transdisciplinary clinical trial staff. This new building 1960s and became a National Cancer team approaches to advance the provides an exceptional environment Institute-designated cancer center science and treatment of cancer. for patients, family and caregiver in 1974, shortly after the National Teams have been developed in cancer experience. Cutting-edge research Cancer Act was placed into law. genomics, tumor microenvironment, and precision medicine is available The Cancer Center received an NCI nanotechnology, imaging, novel to all patients, who have access to “comprehensive” designation in 1990. anticancer drugs, novel anticancer approximately 200 clinical trials. It is one of the longest-standing NCI devices, cancer survivorship, tobacco The Cancer Center was founded with centers, and we are proud to be a part control and cancer health disparities. a strong community orientation and a very distinguished group of only Collaborations with other centers and continues this tradition by addressing 41 NCI-designated comprehensive schools within the institution are an cancer issues that are important to cancer centers in the country. In essential element to the success of the region’s large contingents of addition, the Cancer Center is this research. The Cancer Center has African-Americans, Latinos, Native currently ranked as the #1 cancer strong connections with the Wake Americans, rural poor and pockets hospital in the state of North Carolina Forest Institute for Regenerative of urban poor. The Cancer Center by U.S. News & World Report. Medicine, the Center for Human works closely with the Medical Genomics and Personalized Medicine, The mission of the Cancer Center is to Center’s Maya Angelou Center for Wake Forest Innovations, the Wake improve the lives of cancer patients by Health Equity, which was founded Forest University undergraduate focusing basic, clinical and population by the renowned poet to address Departments of Physics and sciences on the problems of cancer health disparities across the region Chemistry, and the Virginia Tech-Wake prevention, early diagnosis and novel and the nation. We also established a Forest University School of Biomedical treatment. The membership of the Cancer Health Equity initiative in 2012 Engineering and Sciences. Cancer Center is comprised of more with the sole mission of addressing than 125 faculty members from 34 The Cancer Center is the main the needs of our patients in both departments. The Cancer Center’s tertiary referral center for patients in a culturally and linguistically relevant research is divided into four programs: large geographic region. It provides ways. As an example, we hired a Cell Growth and Survival, Cellular a multidisciplinary approach to Hispanic Clinical Trial Navigator Damage and Defense, Clinical treatment in a state-of-the-art facility. in mid-2014 to provide navigation Research, and Cancer Prevention and A six-story expansion of the Cancer services, clinical trial education and Control. To facilitate the scientific and Center opened in December 2013. community outreach specifically translational goals of the programs, The new portion of the building to our Hispanic population in their the Cancer Center has established contains acute care oncology native language. three Centers of Excellence, in brain, inpatient beds and an oncology breast and prostate cancer. intensive-care unit, in addition to 2 The primary functions of the Cancer Registry are to collect relevant data, conduct lifetime CANCER PROGRAM ANNUAL REPORT ANNUAL PROGRAM CANCER follow-up and disseminate cancer information. 2014 Cancer Registry The Cancer Registry works with neoplasms. The registry also collects The Cancer Registry maintains physicians, administrators, researchers selected benign neoplasms and data management and regulatory and health care planners to provide metastatic squamous cell and basal reporting on cancer statistics for support for cancer program cell carcinoma of the skin approved various health care agencies. As development, ensure compliance by the Cancer Committee. The required by law, newly diagnosed with reporting standards, and serve cancer data set includes patient cases are reported to the North as a valuable resource for cancer demographics, cancer identification, Carolina Central Cancer Registry information with the ultimate goal of extent of disease (stage), prognostic (NC-CCR). The data submitted is preventing and controlling cancer. indicators, treatment, recurrence shared with the North American and outcome information. Effective Association of Central Cancer The Cancer Registry functions in Jan. 1, 2012, the registry began the Registries (NAACCR) and the U.S. accordance with guidelines set by collection of the provider-based Centers for Disease Control and the American College of Surgeons clinics cancer cases. The registry Prevention’s National Program of (ACoS). It plays an important began the collection of cancer cases Cancer Registries (CDC-NPCR). role in ensuring that the cancer diagnosed on or after Jan. 1, 2013, for In addition, cancer cases are program is accredited by the Wake Forest Baptist Health Lexington submitted to the Commission on Commission on Cancer and that the Medical Center. Cancer’s National Cancer Data Base Breast Care Center is accredited (NCDB). The NCDB is a comparative by the National Accreditation Follow-up is performed annually on database for ongoing assessment Program for Breast Centers. patients in the registry. Follow-up of cancer patient care and is a joint directly benefits patients and The Cancer Registry is involved project of the American College of physicians by reminding them of in managing and analyzing Surgeons (ACoS) and the American the need for medical checkups. clinical cancer information for the Cancer Society. Continued surveillance ensures early purpose of education, research detection of possible recurrence or a The Association of North Carolina and outcome measurement. The new primary. Outcome data provides Cancer Registrars helps cancer primary functions of the Cancer survival information reflecting the registrars in the state maintain their Registry are to collect relevant data, effectiveness of treatment modalities. continuing education hours by conduct lifetime follow-up and The Cancer Registry fulfills requests providing up-to-date educational disseminate cancer information. for cancer data from staff physicians, workshops. The National Cancer The registry also participates in allied health professionals, outside Registrars Association serves as the hospital-based, state and national institutions and requests for follow-up premier education, credentialing and studies, and research projects. information from other cancer advocacy resource for cancer data The Cancer Registry collects all registries. All data requests are professionals. malignant neoplasms and benign handled with the utmost care for the brain and central nervous system patient’s confidentiality. 2014 3 CANCER PROGRAM ANNUAL REPORT ANNUAL PROGRAM CANCER Cancer Committee The Cancer Committee is one of the major components of being an approved cancer program of the American College of Surgeons (ACoS). The committee is responsible for planning, initiating, stimulating and assessing all cancer-related activities. The committee must be a multidisciplinary, standing committee that meets at least quarterly. ACTIVITIES ▶ The Cancer Program Annual Report is compiled and published as an educational activity of the committee. Published journal articles and abstracts are included. ▶ Quality management activities/ improvements are planned, multidisciplinary attendance, total monitored for casefinding, reviewed and implemented case presentation and prospective accuracy of data collection, each year. case presentation. abstracting timeliness, follow-up The College of American and data reporting. ▶ Studies that measure quality ▶ and outcomes are completed so Pathology’s scientifically validated ▶ A subcommittee monitors the that patients receive care that is data elements outlined on the activities of the Breast comparable to national standards. surgical case summary checklist of Care Center. the CAP publication, Reporting on ▶ The AJCC TNM staging by the Cancer Specimens, are reviewed managing physician is monitored. and monitored. ▶ Cancer conferences are reviewed ▶ The Cancer Registry data and and monitored for frequency, activities are evaluated and 4 CANCER PROGRAM ANNUAL REPORT ANNUAL PROGRAM CANCER Cancer Committee Members 2014 Edward Levine, MD, Chair \ Surgical Oncology Amanda Backus, MHA, CAPM, AT-Ret \ Business Planner Joseph Bonkowski,
Load more

Recommended publications
  • Effect of High Glucose Levels on White Adipose Cells and Adipokines—Fuel for the Fire
    Review Effect of High Glucose Levels on White Adipose Cells and Adipokines—Fuel for the Fire Alexander Sorisky Chronic Disease Program, Ottawa Hospital Research Institute, and Departments of Medicine and of Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON K1H 8L6, Canada; [email protected]; Tel.: +1-613-737-8899 Academic Editor: Christa Buechler Received: 17 March 201; Accepted: 26 April 2017; Published: 29 April 2017 Abstract: White adipocytes release adipokines that influence metabolic and vascular health. Hypertrophic obesity is associated with adipose tissue malfunctioning, leading to inflammation and insulin resistance. When pancreatic islet β cells can no longer compensate, the blood glucose concentration rises (hyperglycemia), resulting in type 2 diabetes. Hyperglycaemia may further aggravate adipose cell dysfunction in ~90% of patients with type 2 diabetes who are obese or overweight. This review will focus on the effects of high glucose levels on human adipose cells and the regulation of adipokines. Keywords: adipocytes; hyperglycaemia; adipokines 1. Introduction The mature white adipocyte is distinguished morphologically by the large lipid droplet that occupies most of its interior space. Here, excess energy can be safely stored as an endogenous fuel until metabolic demand requires it to be released. Insulin levels are low in the fasting state, and rise in the post-prandial period. Counter-regulatory hormones, such as epinephrine and glucagon, follow the opposite pattern. Together, they regulate the enzymatic machinery within the adipocyte to achieve the storage of calories as triglyceride following meals, and the release of energy in the form of free fatty acids during fasting or exercise. These well-orchestrated processes maintain metabolic health [1].
    [Show full text]
  • Electrochemotherapy
    Service: Cancer Services Electrochemotherapy Exceptional healthcare, personally delivered What to expect from your treatment You have been told by your doctor that you need electrochemotherapy to treat the cancer that has either spread from your original cancer and /or is suitable for this treatment. This leaflet is designed to answer your questions about the treatment so that you are fully aware of what to expect. What is Electrochemotherapy? Electrochemotherapy is a treatment combining a low dose of a chemotherapy drug (Bleomycin) and an electrical pulse (electroporation) applied directly to the cancer cells using an electrode. This low level dose of chemotherapy drug is not normally effective against the cancer, as it is difficult to get inside the cells. When the electric pulse is applied, the cells form pores allowing the drug to enter and be active against the cancer. What happens to the normal cells? As the chemotherapy drug is most active against the cancer cells, the normal tissue is unaffected. 2 Electrochemotherapy What type of cancer can be treated? Electrochemotherapy is used to treat cancers that have spread to the skin or just below the skin’s surface (metastasised) from the following types of cancer: n All skin cancer (melanoma & non-melanoma) n Breast cancer recurrence n Head and neck cancer, including oral cancer Electrochemotherapy has the advantage of preserving healthy tissue when compared to other treatment options. It can also be used to shrink large cancers making them easier to remove surgically. What happens during the treatment? The chemotherapy drug is usually given into a vein and after a short time a probe is inserted into the cancer, which releases a small electrical current.
    [Show full text]
  • Adipokine Levels and Perilipin Gene Polymorphisms in Obese Turkish Adolescents with Non-Alcoholic Fatty Liver Disease
    65 Erciyes Med J 2018; 40(2): 65-9 • DOI: 10.5152/etd.2018.0010 Adipokine Levels and Perilipin Gene Polymorphisms in Obese Turkish Adolescents with Non-Alcoholic Fatty Liver Disease 1 2 3 4 5 6 ORIGINAL Yavuz Tokgöz , Cahit Barış Erdur , Soheil Akbari , Tuncay Kume , Oya Sayin , Semiha Terlemez , ARTICLE Esra Erdal3, Nur Arslan2 ABSTRACT Objective: The aim of the present study was to evaluate the relationship between adipokines and perilipin (PLIN) polymor- phisms with non-alcoholic fatty liver disease (NAFLD). Cite this article as: Tokgöz Methods: Obese Turkish adolescents were assessed in the study. The patients were divided into two groups: obese (NAFLD Y, Erdur CB, Akbari S, and non-NAFLD) and non-obese. Serum leptin, adiponectin, resistin, and ghrelin levels and PLIN gene analysis (PLIN 1, 4, and Kume T, Sayın O, Terlemez 6) were studied in all patients and healthy control group. Data obtained were compared with those of healthy control group. S, et al. Adipokine Levels and Perilipin Gene Results: Overall, 83 obese adolescents with NAFLD, 123 obese adolescents with normal liver, and 102 healthy non-obese Polymorphisms in Obese adolescents as the control group were evaluated. No significant difference was observed in terms of serum adipokine (leptin, Turkish Adolescents with Non-Alcoholic Fatty Liver adiponectin, resistin, and ghrelin) levels in patients with NAFLD and non-NAFLD obese adolescents. The incidence of major Disease Erciyes Med J alleles of PLIN 6 genotype in obese adolescents without NAFLD was slightly higher than that in the control group (p=0.06). 2018; 40(2): 65-9.
    [Show full text]
  • Scientific Programme for All
    Optimal radiotherapy Scientific Programme for all ESTRO ANNUAL CONFE RENCE 27 - 31 August 2021 Onsite in Madrid, Spain & Online Saturday 28 August 2021 Track: Radiobiology Teaching lecture: The microbiome: Its role in cancer development and treatment response Saturday, 28 August 2021 08:00 - 08:40 N104 Chair: Marc Vooijs - 08:00 The microbiome: Its role in cancer development and treatment response SP - 0004 A. Facciabene (USA) Track: Clinical Teaching lecture: Breast reconstruction and radiotherapy Saturday, 28 August 2021 08:00 - 08:40 Plenary Chair: Philip Poortmans - 08:00 Breast reconstruction and radiotherapy SP - 0005 O. Kaidar-Person (Israel) Track: Clinical Teaching lecture: Neurocognitive changes following radiotherapy for primary brain tumours Saturday, 28 August 2021 08:00 - 08:40 Room 1 Chair: Brigitta G. Baumert - 08:00 Evaluation and care of neurocognitive effects after radiotherapy SP - 0006 M. Klein (The Netherlands) 08:20 Imaging biomarkers of dose-induced damage to critical memory regions SP - 0007 A. Laprie (France Track: Physics Teaching lecture: Independent dose calculation and pre-treatment patient specific QA Saturday, 28 August 2021 08:00 - 08:40 Room 2.1 Chair: Kari Tanderup - 08:00 Independent dose calculation and pre-treatment patient specific QA SP - 0008 P. Carrasco de Fez (Spain) 1 Track: Physics Teaching lecture: Diffusion MRI: How to get started Saturday, 28 August 2021 08:00 - 08:40 Room 2.2 Chair: Tufve Nyholm - Chair: Jan Lagendijk - 08:00 Diffusion MRI: How to get started SP - 0009 R. Tijssen (The Netherlands) Track: RTT Teaching lecture: The role of RTT leadership in advancing multi-disciplinary research Saturday, 28 August 2021 08:00 - 08:40 N103 Chair: Sophie Perryck - 08:00 The role of RTT leadership in advancing multi-disciplinary research SP - 0010 M.
    [Show full text]
  • Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: a New Weapon for Squamous Cell Carcinoma of the Head and Neck?
    cancers Communication Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck? Francesco Longo 1 , Francesco Perri 2,* , Francesco Caponigro 2, Giuseppina Della Vittoria Scarpati 3, Agostino Guida 4 , Ettore Pavone 4, Corrado Aversa 4, Paolo Muto 5, Mario Giuliano 6, Franco Ionna 4 and Raffaele Solla 7 1 Department of Otolaryngology Surgery and Oncology, Ospedale Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy; [email protected] 2 Head and Neck Medical Oncology Unit, INT IRCCS Fondazione G. Pascale, 80131 Naples, Italy; [email protected] 3 Medical Oncology Unit, Hospital of Pollena Trocchia, ASLNA3 sud, 80040 Naples, Italy; [email protected] 4 Department of Otolaryngology Surgery and Oncology, INT IRCCS Fondazione G. Pascale, 80131 Naples, Italy; [email protected] (A.G.); [email protected] (E.P.); [email protected] (C.A.); [email protected] (F.I.) 5 Department of Radiation Oncology, INT IRCCS Fondazione G. Pascale, 80131 Naples, Italy; [email protected] 6 Department of Experimental and Clinical Oncology, University of Naples “Federico II”, 80131 Naples, Italy; [email protected] 7 Italian National Research Council, Institute of Biostructure & Bioimaging, 80131 Naples, Italy; raff[email protected] * Correspondence: [email protected]; Tel.: +0039-0815903362 Received: 19 August 2020; Accepted: 23 September 2020; Published: 28 September 2020 Simple Summary: Squamous cell carcinoma of the head and neck (SCCHN) represents a problem of utmost concern and, for many clinicians and surgeons, an enormous challenge.
    [Show full text]
  • A Neutrophil Activation Signature Predicts Critical Illness and Mortality in COVID-19
    medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20183897; this version posted September 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. A neutrophil activation signature predicts critical illness and mortality in COVID-19 Matthew L. Meizlish,1* Alexander B. Pine,2* Jason D. Bishai,3* George Goshua,2 Emily R. Nadelmann,4 Michael Simonov,5 C-Hong Chang,3 Hanming Zhang,3 Marcus Shallow,3 Parveen Bahel,6 Kent Owusu,7 Yu Yamamoto,5 Tanima Arora,5 Deepak S. Atri,8 Amisha Patel,2 Rana Gbyli,2 Jennifer Kwan,3 Christine H. Won,9 Charles Dela Cruz,9 Christina Price,10 Jonathan Koff,9 Brett A. King,11 Henry M. Rinder,6 F. Perry Wilson,5 John Hwa,3 Stephanie Halene,2 William Damsky,11 David van Dijk,3 Alfred I. Lee2†, Hyung J. Chun3,12 † Affiliations: 1Yale School of Medicine, New Haven, CT 06510, USA 2Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA 3Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA 4Clinical and Translational Research Accelerator, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA 5Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT 06510, USA 6Yale New Haven Health System, New Haven, CT 06510, USA 9Section of Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA 10Section of Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA 11Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA 4Albert Einstein College of Medicine, Bronx, NY 10461, USA 8Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA †Correspondence to: Dr.
    [Show full text]
  • Adipose Recruitment and Activation of Plasmacytoid Dendritic Cells Fuel Metaflammation’
    Diabetes Page 2 of 61 Adipose recruitment and activation of plasmacytoid dendritic cells fuel metaflammation Amrit Raj Ghosh1, Roopkatha Bhattacharya1, Shamik Bhattacharya1, Titli Nargis2, Oindrila Rahaman1, Pritam Duttagupta1, Deblina Raychaudhuri1, Chinky Shiu Chen Liu1, Shounak Roy1, Parasar Ghosh3, Shashi Khanna4, Tamonas Chaudhuri4, Om Tantia4, Stefan Haak5, Santu Bandyopadhyay1, Satinath Mukhopadhyay6, Partha Chakrabarti2 and Dipyaman Ganguly1*. Divisions of 1Cancer Biology & Inflammatory Disorders and 2Cell Biology & Physiology, CSIR- Indian Institute of Chemical Biology, Kolkata, India; 4ILS Hospitals, Kolkata, India; 5Zentrum Allergie & Umwelt (ZAUM), Technical University of Munich and Helmholtz Centre Munich, Munich, Germany; Departments of 3Rheumatology and 6Endocrinology, Institute of Postgraduate Medical Education & Research, Kolkata, India. *Corresponding author: Dipyaman Ganguly, Division of Cancer Biology & Inflammatory Disorders, CSIR-Indian Institute of Chemical Biology, 4 Raja S C Mullick Road, Jadavpur, Kolkata, West Bengal, India, 700032. Phone: 91 33 24730492 Fax: 91 33 2473 5197 Email: [email protected] Running title: PDCs and type I interferons in metaflammation Word count (Main text): 5521 Figures: 7, Table: 1 1 Diabetes Publish Ahead of Print, published online August 25, 2016 Page 3 of 61 Diabetes ABSTRACT In obese individuals the visceral adipose tissue (VAT) becomes seat of chronic low grade inflammation (metaflammation). But the mechanistic link between increased adiposity and metaflammation remains largely
    [Show full text]
  • In Vitro and Numerical Support for Combinatorial Irreversible Electroporation and Electrochemotherapy Glioma Treatment
    Annals of Biomedical Engineering (Ó 2013) DOI: 10.1007/s10439-013-0923-2 In Vitro and Numerical Support for Combinatorial Irreversible Electroporation and Electrochemotherapy Glioma Treatment 1,2 3 3 4 1 R. E. NEAL II, J. H. ROSSMEISL JR., V. D’ALFONSO, J. L. ROBERTSON, P. A. GARCIA, 5 1 S. ELANKUMARAN, and R. V. DAVALOS 1Bioelectromechanical Systems Lab, Virginia Tech – Wake Forest School of Biomedical Engineering and Sciences, Blacksburg, VA, USA; 2Radiology Research Unit, The Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004, Australia; 3Neurology/ Neurosurgery Service and Center for Comparative Oncology, VA-MD Regional College of Veterinary Medicine, Blacksburg, VA, USA; 4Cancer Engineering Group, Virginia Tech – Wake Forest School of Biomedical Engineering and Sciences, Blacksburg, VA, USA; and 5Department of Biomedical Sciences and Pathobiology, VA-MD Regional College of Veterinary Medicine, Blacksburg, VA, USA (Received 12 April 2013; accepted 4 October 2013) Associate Editor Agata A. Exner oversaw the review of this article. Abstract—Irreversible electroporation (IRE) achieves tar- ABBREVIATIONS geted volume non-thermal focal ablation using a series of brief electric pulses to kill cells by disrupting membrane IRE Irreversible electroporation integrity. Electrochemotherapy (ECT) uses lower numbers of ECT Electrochemotherapy sub-lethal electric pulses to disrupt membranes for improved BBB Blood–brain-barrier drug uptake. Malignant glioma (MG) brain tumors are difficult to treat due to diffuse peripheral margins into healthy neural tissue. Here, in vitro experimental data and numerical simulations investigate the feasibility for IRE- INTRODUCTION relevant pulse protocols with adjuvant ECT drugs to enhance MG treatment. Cytotoxicity curves were produced on two Therapeutic options for brain and central nervous glioma cell lines in vitro at multiple pulse strengths and drug system malignancies include radiation therapy, surgical doses with Bleomycin or Carboplatin.
    [Show full text]
  • Adiposity, Dyslipidemia, and Insulin Resistance in Mice with Targeted Deletion of Phospholipid Scramblase 3 (PLSCR3)
    Adiposity, dyslipidemia, and insulin resistance in mice with targeted deletion of phospholipid scramblase 3 (PLSCR3) Therese Wiedmer*†, Ji Zhao*†, Lilin Li*†, Quansheng Zhou*†, Andrea Hevener‡, Jerrold M. Olefsky‡, Linda K. Curtiss§, and Peter J. Sims*†¶ Departments of *Molecular and Experimental Medicine and §Immunology, The Scripps Research Institute, La Jolla, CA 92037; and ‡Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0673 Communicated by Daniel Steinberg, University of California at San Diego, La Jolla, CA, July 28, 2004 (received for review May 3, 2004) The phospholipid scramblases (PLSCR1 to PLSCR4) are a structurally portin-␣, a cofactor of the importin͞Ras͞Ran nucleopore trans- and functionally unique class of proteins, which are products of a port system (23, 24). Once imported into the nucleus, PLSCR1 tetrad of genes conserved from Caenorhabditis elegans to humans. tightly binds to genomic DNA, suggesting a possible role for this The best characterized member of this family, PLSCR1, is implicated protein in nuclear transcription (24). Consistent with a role in in the remodeling of the transbilayer distribution of plasma mem- growth factor receptor signaling, mice with targeted deletion of brane phospholipids but is also required for normal signaling PLSCR1 exhibit defects in cell maturation and proliferation, through select growth factor receptors. Mice with targeted dele- most notably affecting granulocyte production from hematopoi- tion of PLSCR1 display perinatal granulocytopenia due to defective etic precursors in response to select growth factors, and cells response of hematopoietic precursors to granulocyte colony-stim- deficient in PLSCR1 show defects in antiviral response to IFN ulating factor and stem cell factor.
    [Show full text]
  • Intra-Individual Variation of Plasma Adipokine Levels and Utility of Single Measurement of These Biomarkers in Population-Based Studies
    2464 Intra-individual Variation of Plasma Adipokine Levels and Utility of Single Measurement of These Biomarkers in Population-Based Studies Sang-Ah Lee,1 Asha Kallianpur,1 Yong-Bing Xiang,3 Wanqing Wen,1 Qiuyin Cai,1 Dake Liu,3 Sergio Fazio,2 MacRae F. Linton,2 Wei Zheng,1 and Xiao Ou Shu1 1Vanderbilt Epidemiology Center and 2Department of Medicine, Cardiovascular Division, Vanderbilt University Medical Center, Nashville, Tennessee;and 3Department of Epidemiology, Shanghai Cancer Institute, Shanghai, P.R. China Abstract Adipokines, soluble mediators produced by adipo- of a single, random sample with the mean levels from cytes, may link adipose tissue to the inflammatory, the remaining three samples using a bootstrap approach metabolic, and immune dysregulation that characterize and using intra-class correlation coefficients (ICC). many obesity-related diseases. The stability of plasma Spearman correlations between adipokine levels, age, adipokine levels within individuals, their seasonal body mass index (BMI), and waist-to-hip ratio (WHR) variability, intercorrelations, and relationships to well- were estimated. Correlations between plasma adipo- established measures of adiposity are incompletely kine levels from one random sample and the mean of defined. We measured levels of 12 adipokines [inter- the remaining three seasonal samples ranged from 0.57 leukin 1B (IL-1B), IL-6, IL-8, tumor necrosis factor-A to 0.89. Over the 1-year study period, the ICCs for (TNF-A), plasminogen activator inhibitor-1 (PAI-1), adipokine levels ranged from 0.44 (PAI-1) to 0.83 (HGF). high-sensitivity C-reactive protein (hsCRP), monocyte IL-8, MCP-1, and resistin levels were positively associ- chemoattractant protein-1 (MCP-1), nerve growth factor ated with age; HGF and PAI-1 levels were correlated (NGF), leptin, adiponectin, hepatocyte growth factor with BMI and WHR.
    [Show full text]
  • Electrochemotherapy Compared to Surgery for Treatment of Canine Mast Cell Tumours
    in vivo 23: 55-62 (2009) Electrochemotherapy Compared to Surgery for Treatment of Canine Mast Cell Tumours VERONIKA KODRE1, MAJA CEMAZAR2, JANI PECAR3, GREGOR SERSA2, ANDREJ CŐR4 and NATASA TOZON3 1Janssen-Cilag, Division of Johnson-Johnson, Ljubljana; 2Institute of Oncology Ljubljana, Ljubljana; 3University of Ljubljana, Veterinary Faculty, Clinic for Small Animal Medicine and Surgery, Ljubljana; 4University of Ljubljana, Medical Faculty, Ljubljana, Slovenia Abstract. The aim of this study was to evaluate the behaviour, making these tumours challenging to diagnose effectiveness of local treatment electrochemotherapy (ECT) with and to treat. MCTs predominantly occur in middle-aged dogs cisplatin and to compare it with effectiveness of surgery for of many breeds, but more frequently in Boxers, Staffordshire treatment of mast cell tumours (MCT) in dogs. Materials and Bull Terriers, Labradors, Golden Retrievers, Weimeraner and Methods: In the present retrospective study, 25 dogs of different Schnauzers, with no gender predisposition (1). Several breeds with MCT were divided into two treatment groups: factors have been evaluated as prognostic factors, including surgery (16 dogs with 16 tumours) and those whose owners histological grade, which is the most accurate predictor of refused surgery being included into the ECT group (9 dogs with behaviour, as well as clinical stage, size, growth rate, breed, 12 tumours). Response rate and duration of response to the completeness of surgical excision, presence of systemic treatment were evaluated and comparison between groups was signs, argyrophilic nuclear organizer region count, DNA made. Results: The clinical stages of the tumours were stage I in ploidy, matrix metalloproteinases, microvessel density and 4 (45% ) and stage III in 5 (55% ) dogs treated by ECT; 12 abnormal expression of the p53 tumour suppressor gene.
    [Show full text]
  • Macrophage JAK2 Deficiency Protects Against High-Fat Diet-Induced
    www.nature.com/scientificreports OPEN Macrophage JAK2 defciency protects against high-fat diet- induced infammation Received: 6 January 2017 Harsh R. Desai1,2, Tharini Sivasubramaniyam1, Xavier S. Revelo1, Stephanie A. Schroer1, Accepted: 3 July 2017 Cynthia T. Luk1, Prashanth R. Rikkala1, Adam H. Metherel3, David W. Dodington1, Yoo Jin Published: xx xx xxxx Park1, Min Jeong Kim1,4, Joshua A. Rapps1, Rickvinder Besla1, Clinton S. Robbins1,5, Kay-Uwe Wagner6, Richard P. Bazinet3, Daniel A. Winer1,2,7 & Minna Woo1,8 During obesity, macrophages can infltrate metabolic tissues, and contribute to chronic low-grade infammation, and mediate insulin resistance and diabetes. Recent studies have elucidated the metabolic role of JAK2, a key mediator downstream of various cytokines and growth factors. Our study addresses the essential role of macrophage JAK2 in the pathogenesis to obesity-associated infammation and insulin resistance. During high-fat diet (HFD) feeding, macrophage-specifc JAK2 knockout (M-JAK2−/−) mice gained less body weight compared to wildtype littermate control (M-JAK2+/+) mice and were protected from HFD-induced systemic insulin resistance. Histological analysis revealed smaller adipocytes and qPCR analysis showed upregulated expression of some adipogenesis markers in visceral adipose tissue (VAT) of HFD-fed M-JAK2−/− mice. There were decreased crown-like structures in VAT along with reduced mRNA expression of some macrophage markers and chemokines in liver and VAT of HFD-fed M-JAK2−/− mice. Peritoneal macrophages from M-JAK2−/− mice and Jak2 knockdown in macrophage cell line RAW 264.7 also showed lower levels of chemokine expression and reduced phosphorylated STAT3. However, leptin-dependent efects on augmenting chemokine expression in RAW 264.7 cells did not require JAK2.
    [Show full text]